<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39140594</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1748-6963</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>21-22</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Nanomedicine (London, England)</Title><ISOAbbreviation>Nanomedicine (Lond)</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity of trivalent DNA vaccine candidate encapsulated in Chitosan-TPP nanoparticles against EV-A71 and CV-A16.</ArticleTitle><Pagination><StartPage>1779</StartPage><EndPage>1799</EndPage><MedlinePgn>1779-1799</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/17435889.2024.2372243</ELocationID><Abstract><AbstractText><b>Aim:</b> To develop a trivalent DNA vaccine candidate encapsulated in Chitosan-TPP nanoparticles against hand foot and mouth disease (HFMD) and assess its immunogenicity in mice.<b>Materials &amp; methods:</b> Trivalent plasmid carrying the VP1 and VP2 genes of EV-A71, VP1 gene of CV-A16 was encapsulated in Chitosan-TPP nanoparticles through ionic gelation. <i>In vitro</i> characterization and <i>in vivo</i> immunization studies of the CS-TPP-NPs (pIRES-VP121) were performed.<b>Results:</b> Mice administered with CS-TPP NPs (pIRES-VP121) intramuscularly were observed to have the highest IFN-γ response. Sera from mice immunized with the naked pDNA and CS-TPP-NPs (pIRES-VP121) demonstrated good viral clearance against wild-type EV-A71 and CV-A16 in RD cells.<b>Conclusion:</b> CS-TPP-NPs (pIRES-VP121) could serve as a prototype for future development of multivalent HFMD DNA vaccine candidates.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yew</LastName><ForeName>Jia Sheng</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Centre for Virus &amp; Vaccine Research, School of Medical &amp; Life Sciences, Sunway University, Petaling Jaya, 47500, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ong</LastName><ForeName>Seng-Kai</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Biological science, School of Medical &amp; Life Sciences, Sunway University, Petaling Jaya, 47500, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Hui Xuan</ForeName><Initials>HX</Initials><AffiliationInfo><Affiliation>Centre for Virus &amp; Vaccine Research, School of Medical &amp; Life Sciences, Sunway University, Petaling Jaya, 47500, Malaysia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sunway Microbiome Centre, School of Medical &amp; Life Sciences, Sunway University, Petaling Jaya, 47500, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Soon Hao</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Biomedical Science, Faculty of Medicine, Universiti Malaya, Federal Territory of Kuala Lumpur, Kuala Lumpur, 50603, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ong</LastName><ForeName>Kien Chai</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Department of Biomedical Science, Faculty of Medicine, Universiti Malaya, Federal Territory of Kuala Lumpur, Kuala Lumpur, 50603, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Kum Thong</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>Department of Pathology, Faculty of Medicine, Universiti Malaya, Federal Territory of Kuala Lumpur, Kuala Lumpur, 50603, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poh</LastName><ForeName>Chit Laa</ForeName><Initials>CL</Initials><Identifier Source="ORCID">0000-0001-8475-6291</Identifier><AffiliationInfo><Affiliation>Centre for Virus &amp; Vaccine Research, School of Medical &amp; Life Sciences, Sunway University, Petaling Jaya, 47500, Malaysia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ALPS Global Holding Berhad, The ICON, No.1, Off Jalan Tun Razak, Kuala Lumpur, 50400, Malaysia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>STR-IRNGS-SMLS-CVVR-01-2021</GrantID><Agency>Sunway University International Network Grant Scheme</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nanomedicine (Lond)</MedlineTA><NlmUniqueID>101278111</NlmUniqueID><ISSNLinking>1743-5889</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019444">Vaccines, DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>9012-76-4</RegistryNumber><NameOfSubstance UI="D048271">Chitosan</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical><Chemical><RegistryNumber>NU43IAG5BC</RegistryNumber><NameOfSubstance UI="C005692">triphosphoric acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011122">Polyphosphates</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019444" MajorTopicYN="Y">Vaccines, DNA</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048271" MajorTopicYN="Y">Chitosan</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="Y">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010957" MajorTopicYN="N">Plasmids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011122" MajorTopicYN="N">Polyphosphates</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>[Box: see text].</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DNA</Keyword><Keyword MajorTopicYN="N">immunology/infectious diseases</Keyword><Keyword MajorTopicYN="N">nanoparticles</Keyword><Keyword MajorTopicYN="N">vaccines</Keyword><Keyword MajorTopicYN="N">viruses</Keyword></KeywordList><CoiStatement>The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>20</Day><Hour>12</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>14</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>14</Day><Hour>8</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39140594</ArticleId><ArticleId IdType="pmc">PMC11418279</ArticleId><ArticleId IdType="doi">10.1080/17435889.2024.2372243</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Osterback R, Vuorinen T, Linna M, et al. . Coxsackievirus A6 and hand, foot, and mouth disease, Finland. Emerg Infect Dis. 2009;15(9):1485–1488. doi:10.3201/eid1509.090438</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1509.090438</ArticleId><ArticleId IdType="pmc">PMC2819858</ArticleId><ArticleId IdType="pubmed">19788821</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozzetto B, Gaudin OG. COXSACKIEVIRUSES (PICORNAVIRIDAE). Encycloped Virol. 1999:305–311. doi:10.1006/rwvi.1999.0057</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/rwvi.1999.0057</ArticleId></ArticleIdList></Reference><Reference><Citation>Smyth MS, Martin JH. Picornavirus uncoating. Molecular pathology: MP. 2002;55(4):214–219. doi:10.1136/mp.55.4.214</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/mp.55.4.214</ArticleId><ArticleId IdType="pmc">PMC1187181</ArticleId><ArticleId IdType="pubmed">12147709</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang CY, Liu CC. Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease. Exp Rev Vacc. 2018;17(9):819–831. doi:10.1080/14760584.2018.1510326</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2018.1510326</ArticleId><ArticleId IdType="pubmed">30095317</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalani S, Gew LT, Poh CL. Antiviral peptides against Enterovirus A71 causing hand, foot and mouth disease. Peptides. 2021;136:170443. doi:10.1016/j.peptides.2020.170443</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2020.170443</ArticleId><ArticleId IdType="pmc">PMC7648656</ArticleId><ArticleId IdType="pubmed">33171280</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Boeckel TP, Takahashi S, Liao Q, et al. . Hand, foot, and mouth disease in China: critical community size and spatial vaccination strategies. Scient Reports. 2016;6:25248. doi:10.1038/srep25248</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep25248</ArticleId><ArticleId IdType="pmc">PMC4850478</ArticleId><ArticleId IdType="pubmed">27125917</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Tian J, Wang Y, et al. . The burden of hand, foot, and mouth disease among children under different vaccination scenarios in China: a dynamic modelling study. BMC Infect Dis. 2021;21(1):650. doi:10.1186/s12879-021-06157-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-06157-w</ArticleId><ArticleId IdType="pmc">PMC8259139</ArticleId><ArticleId IdType="pubmed">34225650</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders B, Koldijk M, Schuitemaker H. Inactivated Viral Vaccines. In: Nunnally BK, Turula VE, Sitrin RD, editors. Vaccine Analysis: Strategies, Principles, and Control. Berlin, Heidelberg: Springer Berlin Heidelberg; 2015. p. 45–80. doi:10.1007/978-3-662-45024-6_2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-662-45024-6_2</ArticleId></ArticleIdList></Reference><Reference><Citation>Aswathyraj S, Arunkumar G, Alidjinou EK, et al. . Hand, foot and mouth disease (HFMD): emerging epidemiology and the need for a vaccine strategy. Med Microbiol Immunol. 2016;205(5):397–407. doi:10.1007/s00430-016-0465-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00430-016-0465-y</ArticleId><ArticleId IdType="pubmed">27406374</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Guo MS, Wu SR, et al. . Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles. Antiviral Res. 2016;129:58–66. doi:10.1016/j.antiviral.2016.02.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.02.008</ArticleId><ArticleId IdType="pubmed">26899790</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Dai W, Zhang C, et al. . A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity. Emerg Microb Infect. 2018;7(1):94. doi:10.1038/s41426-018-0094-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41426-018-0094-1</ArticleId><ArticleId IdType="pmc">PMC5959873</ArticleId><ArticleId IdType="pubmed">29777102</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol. Rev. 2011;239(1):62–84. doi:10.1111/j.1600-065X.2010.00980.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.2010.00980.x</ArticleId><ArticleId IdType="pubmed">21198665</ArticleId></ArticleIdList></Reference><Reference><Citation>Jazayeri SD, Poh CL. Recent advances in delivery of veterinary DNA vaccines against avian pathogens. Veter Res. 2019;50(1):78. doi:10.1186/s13567-019-0698-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13567-019-0698-z</ArticleId><ArticleId IdType="pmc">PMC6785882</ArticleId><ArticleId IdType="pubmed">31601266</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen DN, Green JJ, Chan JM, et al. . Polymeric materials for gene delivery and DNA vaccination. Advan Mater. 2009;21(8):847–867. doi:10.1002/adma.200801478</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adma.200801478</ArticleId><ArticleId IdType="pmc">PMC5391878</ArticleId><ArticleId IdType="pubmed">28413262</ArticleId></ArticleIdList></Reference><Reference><Citation>Quaak SG, Haanen JB, Beijnen JH, et al. . Naked plasmid DNA formulation: effect of different disaccharides on stability after lyophilisation. AAPS PharmSciTech. 2010;11(1):344–350. doi:10.1208/s12249-010-9391-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12249-010-9391-2</ArticleId><ArticleId IdType="pmc">PMC2850488</ArticleId><ArticleId IdType="pubmed">20204715</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y, Rodriguez S, Hebel H. DNA vaccine manufacture: scale and quality. Expert Rev Vacc. 2009;8(9):1277–1291. doi:10.1586/erv.09.84</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erv.09.84</ArticleId><ArticleId IdType="pubmed">19722898</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan AS, Broderick KE, Sardesai NY. Clinical development of intramuscular electroporation: providing a “boost” for DNA vaccines. Meth Mol Biolo. 2014;1121:279–289. doi:10.1007/978-1-4614-9632-8_25</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4614-9632-8_25</ArticleId><ArticleId IdType="pubmed">24510832</ArticleId></ArticleIdList></Reference><Reference><Citation>Coban C, Kobiyama K, Aoshi T, et al. . Novel strategies to improve DNA vaccine immunogenicity. Curr Gene Ther. 2011;11(6):479–484. doi:10.2174/156652311798192815</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156652311798192815</ArticleId><ArticleId IdType="pubmed">22023477</ArticleId></ArticleIdList></Reference><Reference><Citation>Deering RP, Kommareddy S, Ulmer JB, et al. . Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines. Exp Opin Drug Del. 2014;11(6):885–899. doi:10.1517/17425247.2014.901308</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/17425247.2014.901308</ArticleId><ArticleId IdType="pubmed">24665982</ArticleId></ArticleIdList></Reference><Reference><Citation>Iurescia S, Fioretti D, Rinaldi M. Strategies for improving DNA vaccine performance. Meth Mol Biol. 2014;1143:21–31. doi:10.1007/978-1-4939-0410-5_3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-0410-5_3</ArticleId><ArticleId IdType="pubmed">24715280</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Phoon MC, et al. . Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res. 2007;125(1):61–68. doi:10.1016/j.virusres.2006.12.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2006.12.005</ArticleId><ArticleId IdType="pubmed">17222936</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chou AH, Lien SP, et al. . Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine. 2011;29(26):4362–4372. doi:10.1016/j.vaccine.2011.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.010</ArticleId><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YX, Zhao H, Cao RY, et al. . Recombinant tandem multi-linear neutralizing epitopes of human enterovirus 71 elicited protective immunity in mice. Virol J. 2014;11:79. doi:10.1186/1743-422x-11-79</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422x-11-79</ArticleId><ArticleId IdType="pmc">PMC4030048</ArticleId><ArticleId IdType="pubmed">24885030</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J, Huang X, Liu Q, et al. . Identification of conserved neutralizing linear epitopes within the VP1 protein of coxsackievirus A16. Vaccine. 2013;31(17):2130–2136. doi:10.1016/j.vaccine.2013.02.051</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.02.051</ArticleId><ArticleId IdType="pubmed">23499595</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauková L, Konečná B, Janovičová Ľ, et al. . Deoxyribonucleases and their applications in biomedicine. Biomolecules. 2020;10(7):1036. doi:10.3390/biom10071036</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10071036</ArticleId><ArticleId IdType="pmc">PMC7407206</ArticleId><ArticleId IdType="pubmed">32664541</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun CH, Cho CS. Nanoparticles to Improve the Efficacy of Vaccines. Pharmaceutics. 2020;12(5):418. doi:10.3390/pharmaceutics12050418</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics12050418</ArticleId><ArticleId IdType="pmc">PMC7284527</ArticleId><ArticleId IdType="pubmed">32370192</ArticleId></ArticleIdList></Reference><Reference><Citation>Elieh-Ali-Komi D, Hamblin MR. Chitin and chitosan: production and application of versatile biomedical nanomaterials. Inter J Advan Res. 2016;4(3):411–427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5094803</ArticleId><ArticleId IdType="pubmed">27819009</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Kumar AJBS. Performance, Applications, et al. . Chitosan as a biomedical material: properties and applications. 2017:139–153.</Citation></Reference><Reference><Citation>Mohammed MA, Syeda JTM, Wasan KM, et al. . An overview of chitosan nanoparticles and its application in non-parenteral drug delivery. Pharmaceutics. 2017;9(4):53. doi:10.3390/pharmaceutics9040053</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics9040053</ArticleId><ArticleId IdType="pmc">PMC5750659</ArticleId><ArticleId IdType="pubmed">29156634</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta PN, Mahor S, Rawat A, et al. . Lectin anchored stabilized biodegradable nanoparticles for oral immunization 1. Development and in vitro evaluation. Inter J Pharmaceut. 2006;318(1–2):163–173. doi:10.1016/j.ijpharm.2006.03.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2006.03.017</ArticleId><ArticleId IdType="pubmed">16621367</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Tan YF, Wong YS, et al. . Recent advances in chitosan-based carriers for gene delivery. Marine Drugs. 2019;17(6):381. doi:10.3390/md17060381</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/md17060381</ArticleId><ArticleId IdType="pmc">PMC6627531</ArticleId><ArticleId IdType="pubmed">31242678</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao K, Zhang Y, Zhang X, et al. . Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in chitosan nanoparticles. Inter J Nanomed. 2014;9:389–402. doi:10.2147/IJN.S54226</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJN.S54226</ArticleId><ArticleId IdType="pmc">PMC3890423</ArticleId><ArticleId IdType="pubmed">24426783</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehghan S, Tafaghodi M, Bolourieh T, et al. . Rabbit nasal immunization against influenza by dry-powder form of chitosan nanospheres encapsulated with influenza whole virus and adjuvants. Inter J Pharmaceut. 2014;475(1–2):1–8. doi:10.1016/j.ijpharm.2014.08.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2014.08.032</ArticleId><ArticleId IdType="pubmed">25148732</ArticleId></ArticleIdList></Reference><Reference><Citation>Bande F, Arshad SS, Bejo MH, et al. . Development and immunogenic potentials of chitosan-saponin encapsulated DNA vaccine against avian infectious bronchitis coronavirus. Microb Pathog. 2020;149:104560. doi:10.1016/j.micpath.2020.104560</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2020.104560</ArticleId><ArticleId IdType="pmc">PMC7556284</ArticleId><ArticleId IdType="pubmed">33068733</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuen CY, Fakurazi S, Othman SS, et al. . Increased loading, efficacy and sustained release of silibinin, a poorly soluble drug using hydrophobically-modified chitosan nanoparticles for enhanced delivery of anticancer drug delivery systems. Nanomaterials (Basel, Switzerland). 2017;7(11):379. doi:10.3390/nano7110379</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nano7110379</ArticleId><ArticleId IdType="pmc">PMC5707596</ArticleId><ArticleId IdType="pubmed">29117121</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunes R, Serra AS, Simaite A, et al. . Modulation of chitosan-TPP nanoparticle properties for plasmid DNA vaccines delivery. Polymers. 2022;14(7):1443. doi:10.3390/polym14071443</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/polym14071443</ArticleId><ArticleId IdType="pmc">PMC9003200</ArticleId><ArticleId IdType="pubmed">35406316</ArticleId></ArticleIdList></Reference><Reference><Citation>Othman N, Masarudin MJ, Kuen CY, et al. . Synthesis and optimization of chitosan nanoparticles loaded with L-ascorbic acid and thymoquinone. Nanomaterials (Basel, Switzerland). 2018;8(11):920. doi:10.3390/nano8110920</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nano8110920</ArticleId><ArticleId IdType="pmc">PMC6267081</ArticleId><ArticleId IdType="pubmed">30405074</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunes R, Sousa Â, Simaite A, et al. . Sub-100 nm chitosan-triphosphate-DNA nanoparticles for delivery of DNA vaccines. Proceedings. 2021;78 (1):12. doi:10.3390/IECP2020-08653</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/IECP2020-08653</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimesh S, Thibault MM, Lavertu M, et al. . Enhanced gene delivery mediated by low molecular weight chitosan/DNA complexes: effect of pH and serum. Mol Biotechnol. 2010;46(2):182–196. doi:10.1007/s12033-010-9286-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12033-010-9286-1</ArticleId><ArticleId IdType="pmc">PMC2929434</ArticleId><ArticleId IdType="pubmed">20454872</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan SH, Ong KC, Perera D, et al. . A monoclonal antibody to ameliorate central nervous system infection and improve survival in a murine model of human Enterovirus-A71 encephalomyelitis. Antiviral Res. 2016;132:196–203. doi:10.1016/j.antiviral.2016.04.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2016.04.015</ArticleId><ArticleId IdType="pubmed">27340013</ArticleId></ArticleIdList></Reference><Reference><Citation>Heng WT, Lim HX, Tan KO, et al. . Validation of multi-epitope peptides encapsulated in PLGA nanoparticles against influenza A virus. Pharm Res. 2023;40(8):1999–2025. doi:10.1007/s11095-023-03540-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-023-03540-x</ArticleId><ArticleId IdType="pubmed">37344603</ArticleId></ArticleIdList></Reference><Reference><Citation>Amrun SN, Tan JJL, Rickett NY, et al. . TREM-1 activation is a potential key regulator in driving severe pathogenesis of enterovirus A71 infection. Scient Reports. 2020;10(1):3810. doi:10.1038/s41598-020-60761-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-60761-5</ArticleId><ArticleId IdType="pmc">PMC7052206</ArticleId><ArticleId IdType="pubmed">32123257</ArticleId></ArticleIdList></Reference><Reference><Citation>NikNadia N, Sam IC, Rampal S, et al. . Cyclical patterns of hand, foot and mouth disease caused by enterovirus A71 in Malaysia. PLoS Neglected Trop Dis. 2016;10(3):e0004562. doi:10.1371/journal.pntd.0004562</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0004562</ArticleId><ArticleId IdType="pmc">PMC4806993</ArticleId><ArticleId IdType="pubmed">27010319</ArticleId></ArticleIdList></Reference><Reference><Citation>Aw-Yong KL, Sam IC, Koh MT, et al. . Causative agents of hand, foot and mouth disease in University Malaya Medical Centre, Kuala Lumpur, Malaysia in 2012–2013. Tropical Biomed. 2017;34(1):240–248.</Citation><ArticleIdList><ArticleId IdType="pubmed">33593003</ArticleId></ArticleIdList></Reference><Reference><Citation>Jesus S, Marques AP, Duarte A, et al. . Chitosan nanoparticles: shedding light on immunotoxicity and hemocompatibility. Front Bioengin Biotechnol. 2020;8:100. doi:10.3389/fbioe.2020.00100</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fbioe.2020.00100</ArticleId><ArticleId IdType="pmc">PMC7047933</ArticleId><ArticleId IdType="pubmed">32154232</ArticleId></ArticleIdList></Reference><Reference><Citation>López-García J, Lehocký M, Humpolíček P, et al. . HaCaT keratinocytes response on antimicrobial atelocollagen substrates: extent of cytotoxicity, cell viability and proliferation. J Funct Biomat. 2014;5(2):43–57. doi:10.3390/jfb5020043</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jfb5020043</ArticleId><ArticleId IdType="pmc">PMC4099973</ArticleId><ArticleId IdType="pubmed">24956439</ArticleId></ArticleIdList></Reference><Reference><Citation>Puenpa J, Wanlapakorn N, Vongpunsawad S, et al. . The history of enterovirus A71 outbreaks and molecular epidemiology in the Asia-Pacific region. J Biomed Sci. 2019;26(1):75. doi:10.1186/s12929-019-0573-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0573-2</ArticleId><ArticleId IdType="pmc">PMC6798416</ArticleId><ArticleId IdType="pubmed">31627753</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung WS, Bakar SA, Sekawi Z, et al. . DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vacc Ther. 2007;5:6. doi:10.1186/1479-0556-5-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-0556-5-6</ArticleId><ArticleId IdType="pmc">PMC3225814</ArticleId><ArticleId IdType="pubmed">17445254</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Zhang Y, Li H, et al. . Hand-foot-and-mouth disease-associated enterovirus and the development of multivalent HFMD vaccines. Inter JMol Sci. 2022;24(1):169. doi:10.3390/ijms24010169</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24010169</ArticleId><ArticleId IdType="pmc">PMC9820767</ArticleId><ArticleId IdType="pubmed">36613612</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Fang H, Chen Z, et al. . Shape effects of nanoparticles conjugated with cell-penetrating peptides (HIV Tat PTD) on CHO cell uptake. 2008;19(9):1880–1887. doi:10.1021/bc800160b</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bc800160b</ArticleId><ArticleId IdType="pmc">PMC2697497</ArticleId><ArticleId IdType="pubmed">18690739</ArticleId></ArticleIdList></Reference><Reference><Citation>Chithrani BD, Ghazani AA, Chan WCJNl. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. 2006;6(4):662–668. doi:10.1021/nl052396o</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/nl052396o</ArticleId><ArticleId IdType="pubmed">16608261</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y, Lapitsky YJC, Biointerfaces SB. Biomolecular uptake effects on chitosan/tripolyphosphate micro-and nanoparticle stability. 2020;193:111081. doi:10.1016/j.colsurfb.2020.111081</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.colsurfb.2020.111081</ArticleId><ArticleId IdType="pubmed">32403037</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Lapitsky Y. On the kinetics of chitosan/tripolyphosphate micro- and nanogel aggregation and their effects on particle polydispersity. J Coll Interf Sci. 2017;486:27–37. doi:10.1016/j.jcis.2016.09.050</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcis.2016.09.050</ArticleId><ArticleId IdType="pubmed">27693518</ArticleId></ArticleIdList></Reference><Reference><Citation>Masarudin MJ, Cutts SM, Evison BJ, et al. . Factors determining the stability, size distribution, and cellular accumulation of small, monodisperse chitosan nanoparticles as candidate vectors for anticancer drug delivery: application to the passive encapsulation of [(14)C]-doxorubicin. Nanotechnol Sci Appl. 2015;8:67–80. doi:10.2147/NSA.S91785</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/NSA.S91785</ArticleId><ArticleId IdType="pmc">PMC4686320</ArticleId><ArticleId IdType="pubmed">26715842</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke SP, editor. Development of Hierarchical Magnetic Nanocomposite Materials for Biomedical Applications. Dublin: Dissertation/Ph.D, Dublin City University; 2013.</Citation></Reference><Reference><Citation>Hallaj-Nezhadi S, Valizadeh H, Dastmalchi S, et al. . Preparation of chitosan-plasmid DNA nanoparticles encoding interleukin-12 and their expression in CT-26 colon carcinoma cells. J Pharm Pharmaceut Sci. 2011;14(2):181–195. doi:10.18433/J3TP4T</Citation><ArticleIdList><ArticleId IdType="doi">10.18433/J3TP4T</ArticleId><ArticleId IdType="pubmed">21733408</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-nemrawi N, Alsharif S, Dave R. Preparation of chitosan-tpp nanoparticles: the influence of chitosan polymeric properties and formulation variables. Inter J Appl Pharmaceut. 2018;10:60. doi:10.22159/ijap.2018v10i5.26375</Citation><ArticleIdList><ArticleId IdType="doi">10.22159/ijap.2018v10i5.26375</ArticleId></ArticleIdList></Reference><Reference><Citation>Iswanti FC, Nurulita I, Djauzi S, et al. . Preparation, characterization, and evaluation of chitosan-based nanoparticles as CpG ODN carriers. Biotechnology &amp; Biotechnological Equipment. 2019;33(1):390–396. doi:10.1080/13102818.2019.1578690</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13102818.2019.1578690</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma F, Wang Y, Yang G. The modulation of chitosan-DNA interaction by concentration and pH in solution. Polymers. 2019;11(4):646. doi:10.3390/polym11040646</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/polym11040646</ArticleId><ArticleId IdType="pmc">PMC6523332</ArticleId><ArticleId IdType="pubmed">30970619</ArticleId></ArticleIdList></Reference><Reference><Citation>Guadarrama-Escobar OR, Serrano-Castañeda P, Anguiano-Almazán E, et al. . Chitosan nanoparticles as oral drug carriers. InterJ Mol Sci. 2023;24(5):4289. doi:10.3390/ijms24054289</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24054289</ArticleId><ArticleId IdType="pmc">PMC10001540</ArticleId><ArticleId IdType="pubmed">36901719</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowman K, Leong KW. Chitosan nanoparticles for oral drug and gene delivery. Inter J Nanomed. 2006;1(2):117–128. doi:10.2147/nano.2006.1.2.117</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/nano.2006.1.2.117</ArticleId><ArticleId IdType="pmc">PMC2426784</ArticleId><ArticleId IdType="pubmed">17722528</ArticleId></ArticleIdList></Reference><Reference><Citation>Valente JFA, Pereira P, Sousa A, et al. . Effect of plasmid DNA size on chitosan or polyethyleneimine polyplexes formulation. Polymers. 2021;13(5):793. doi:10.3390/polym13050793</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/polym13050793</ArticleId><ArticleId IdType="pmc">PMC7962013</ArticleId><ArticleId IdType="pubmed">33807586</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto M, Morimoto M, Saimoto H, et al. . Gene transfer by DNA/mannosylated chitosan complexes into mouse peritoneal macrophages. Biotechnol Lett. 2006;28(11):815–821. doi:10.1007/s10529-006-9006-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10529-006-9006-x</ArticleId><ArticleId IdType="pubmed">16786247</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernández Fernández E, Santos-Carballal B, Weber WM, et al. . Chitosan as a non-viral co-transfection system in a cystic fibrosis cell line. Inter J Pharmaceut. 2016;502(1–2):1–9. doi:10.1016/j.ijpharm.2016.01.083</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2016.01.083</ArticleId><ArticleId IdType="pubmed">26875537</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLaughlin FC, Mumper RJ, Wang J, et al. . Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery. J Control Rel. 1998;56(1–3):259–272. doi:10.1016/S0168-3659(98)00097-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0168-3659(98)00097-2</ArticleId><ArticleId IdType="pubmed">9801449</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T, Ishii T, Okahata Y. In vitro gene delivery mediated by chitosan. effect of pH, serum, and molecular mass of chitosan on the transfection efficiency. Biomaterials. 2001;22(15):2075–2080. doi:10.1016/S0142-9612(00)00385-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0142-9612(00)00385-9</ArticleId><ArticleId IdType="pubmed">11432586</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Yu SB, Wu FL, et al. . Transfection of primary chondrocytes using chitosan-pEGFP nanoparticles. J Control Rel. 2006;112(2):223–228. doi:10.1016/j.jconrel.2006.01.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2006.01.016</ArticleId><ArticleId IdType="pubmed">16556468</ArticleId></ArticleIdList></Reference><Reference><Citation>Aibani N, Rai R, Patel P, et al. . Chitosan nanoparticles at the biological interface: implications for drug delivery. Pharmaceutics. 2021;13(10):1686. doi:10.3390/pharmaceutics13101686</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics13101686</ArticleId><ArticleId IdType="pmc">PMC8540112</ArticleId><ArticleId IdType="pubmed">34683979</ArticleId></ArticleIdList></Reference><Reference><Citation>Koppolu B, Zaharoff DA. The effect of antigen encapsulation in chitosan particles on uptake, activation and presentation by antigen presenting cells. Biomaterials. 2013;34(9):2359–2369. doi:10.1016/j.biomaterials.2012.11.066</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2012.11.066</ArticleId><ArticleId IdType="pmc">PMC3552013</ArticleId><ArticleId IdType="pubmed">23274070</ArticleId></ArticleIdList></Reference><Reference><Citation>Raftery R, O'Brien FJ, Cryan SA. Chitosan for gene delivery and orthopedic tissue engineering applications. Molecules (Basel, Switzerland). 2013;18(5):5611–5647. doi:10.3390/molecules18055611</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules18055611</ArticleId><ArticleId IdType="pmc">PMC6270408</ArticleId><ArticleId IdType="pubmed">23676471</ArticleId></ArticleIdList></Reference><Reference><Citation>McConnell KI, Shamsudeen S, Meraz IM, et al. . Reduced cationic nanoparticle cytotoxicity based on serum masking of surface potential. J Biomed Nanotechnol. 2016;12(1):154–164. doi:10.1166/jbn.2016.2134</Citation><ArticleIdList><ArticleId IdType="doi">10.1166/jbn.2016.2134</ArticleId><ArticleId IdType="pmc">PMC4970519</ArticleId><ArticleId IdType="pubmed">27301181</ArticleId></ArticleIdList></Reference><Reference><Citation>Jevprasesphant R, Penny J, Jalal R, et al. . The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Inter J Pharmaceutics. 2003;252(1–2):263–266. doi:10.1016/S0378-5173(02)00623-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0378-5173(02)00623-3</ArticleId><ArticleId IdType="pubmed">12550802</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer D, Li Y, Ahlemeyer B, et al. . In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials. 2003;24(7):1121–1131. doi:10.1016/S0142-9612(02)00445-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0142-9612(02)00445-3</ArticleId><ArticleId IdType="pubmed">12527253</ArticleId></ArticleIdList></Reference><Reference><Citation>Frigaard J, Jensen JL, Galtung HK, et al. . The potential of chitosan in nanomedicine: an overview of the cytotoxicity of chitosan based nanoparticles. Front Pharmacol. 2022;13:880377. doi:10.3389/fphar.2022.880377</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.880377</ArticleId><ArticleId IdType="pmc">PMC9115560</ArticleId><ArticleId IdType="pubmed">35600854</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann G. Nucleic acid immunity. Adv Immunol. 2017;133:121–169. doi:10.1016/bs.ai.2016.11.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.ai.2016.11.001</ArticleId><ArticleId IdType="pmc">PMC7112058</ArticleId><ArticleId IdType="pubmed">28215278</ArticleId></ArticleIdList></Reference><Reference><Citation>Lončarević AIvanković M, Rogina A. Lysozyme-induced degradation of chitosan: the characterisation of degraded chitosan scaffolds. JTissue Repair Regen. 2017;1(1):12–22. doi:10.14302/issn.2640-6403.jtrr-17-1840</Citation><ArticleIdList><ArticleId IdType="doi">10.14302/issn.2640-6403.jtrr-17-1840</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraboschi P, Ciceri S, Grisenti P. Applications of lysozyme, an innate immune defense factor, as an alternative antibiotic. Antibiotics (Basel, Switzerland). 2021;10(12):1534. doi:10.3390/antibiotics10121534</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics10121534</ArticleId><ArticleId IdType="pmc">PMC8698798</ArticleId><ArticleId IdType="pubmed">34943746</ArticleId></ArticleIdList></Reference><Reference><Citation>Hipolito VEB, Ospina-Escobar E, Botelho RJ. Lysosome remodelling and adaptation during phagocyte activation. Cell Microbiol. 2018;20(4). doi:10.1111/cmi.12824</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cmi.12824</ArticleId><ArticleId IdType="pubmed">29349904</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu YX, Li XP, Kadir Z, et al. . Molecular adjuvant interleukin-33 enhances the antifertility effect of Lagurus lagurus zona pellucida 3 DNA vaccine administered by the mucosal route. Brazilian J Med Biolog Res. 2013;46(12):1064–1073. doi:10.1590/1414-431X20133126</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1414-431X20133126</ArticleId><ArticleId IdType="pmc">PMC3935279</ArticleId><ArticleId IdType="pubmed">24345916</ArticleId></ArticleIdList></Reference><Reference><Citation>Highton AJ, Girardin A, Bell GM, et al. . Chitosan gel vaccine protects against tumour growth in an intracaecal mouse model of cancer by modulating systemic immune responses. BMC Immunol. 2016;17(1):39. doi:10.1186/s12865-016-0178-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12865-016-0178-4</ArticleId><ArticleId IdType="pmc">PMC5069793</ArticleId><ArticleId IdType="pubmed">27756214</ArticleId></ArticleIdList></Reference><Reference><Citation>Han HD, Byeon Y, Jang JH, et al. . In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy. Scient Reports. 2016;6:38348. doi:10.1038/srep38348</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep38348</ArticleId><ArticleId IdType="pmc">PMC5133713</ArticleId><ArticleId IdType="pubmed">27910914</ArticleId></ArticleIdList></Reference><Reference><Citation>Heffernan MJ, Zaharoff DA, Fallon JK, et al. . In vivo efficacy of a chitosan/IL-12 adjuvant system for protein-based vaccines. Biomaterials. 2011;32(3):926–932. doi:10.1016/j.biomaterials.2010.09.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2010.09.058</ArticleId><ArticleId IdType="pmc">PMC2992965</ArticleId><ArticleId IdType="pubmed">20965561</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro F, Cardoso AP, Gonçalves RM, et al. . Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front Immunol. 2018;9:847. doi:10.3389/fimmu.2018.00847</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00847</ArticleId><ArticleId IdType="pmc">PMC5945880</ArticleId><ArticleId IdType="pubmed">29780381</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao Y, Liu X, Han C, et al. . Identification of IFN-γ-producing innate B cells. Cell Res. 2014;24(2):161–176. doi:10.1038/cr.2013.155</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2013.155</ArticleId><ArticleId IdType="pmc">PMC3915900</ArticleId><ArticleId IdType="pubmed">24296781</ArticleId></ArticleIdList></Reference><Reference><Citation>Darwich L, Coma G, Peña R, et al. . Secretion of interferon-gamma by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18. Immunology. 2009;126(3):386–393. doi:10.1111/j.1365-2567.2008.02905.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2567.2008.02905.x</ArticleId><ArticleId IdType="pmc">PMC2669819</ArticleId><ArticleId IdType="pubmed">18759749</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>